Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
13 Junho 2023 - 8:00AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced it will showcase
its latest Endocrinology Rare Disease programs, data, and research
in growth hormone deficiency, hypoparathyroidism, achondroplasia,
and Turner Syndrome at ENDO 2023, the annual meeting of the
Endocrine Society being held June 15-18 in Chicago.
An oral presentation on Saturday, June 17, will feature Phase 3
Week 52 data for TransCon PTH in adults with hypoparathyroidism,
and five additional poster presentations listed in the table below
will showcase other Ascendis programs and data. In addition,
Ascendis will host booth #1628, booth #1740, and two product
theaters during ENDO 2023.
ABSTRACT |
|
PRESENTING AUTHOR |
Hypoparathyroidism |
|
|
Long-Term Efficacy and Safety of TransCon PTH in Adults
with Hypoparathyroidism: 52-Week Results from the Open-Label
Extension of the PaTHway Phase 3 TrialOral presentation,
Saturday, June 17, 4:30-4:45 pm (CDT))Session: OR23-05 |
|
Bart L. Clarke, M.D. |
Clinical and Economic Burden of Postsurgical Chronic
Hypoparathyroidism: A U.S. Medicare Retrospective
AnalysisPoster, Saturday, June 17, 1:00 - 2:00 pm (CDT)
Session P69 Poster: SAT-233 |
|
Wahidullah Noori, Pharm. D., M.S. |
Achondroplasia |
|
|
Significantly Improved Annual Height Velocity with
Once-Weekly TransCon CNP in Children with Achondroplasia: The
ACcomplisH Phase 2, Randomized, Double-Blind, Placebo-Controlled,
Dose-Escalation TrialPoster, Thursday, Thursday, June 15,
12:30 - 1:30 pm (CDT)Session P10 Poster: THU-156 |
|
Ravi Savarirayan, MBBS, FRACP, HGSA, MD |
Growth Hormone Deficiency |
|
|
Prevalence of Comorbidities Among Treated and Untreated
Adults with Suspected Growth Hormone DeficiencyLate
Breaker: Poster, Saturday, June 17, 1:00 – 2:00 pm (CDT) Session
P87 Poster SAT-611 |
|
Subhara Raveendran, Ph.D |
Subanalysis by Tanner Stage in Phase 3 Trials in Children
and Adolescents with Growth Hormone Deficiency Treated with
LonapegsomatropinPoster, Thursday, June 15, 12:30 – 1:30
pm (CDT) Session P10 Poster: THU-173 |
|
Paul Hofman, MBChB, Dip Obs, FRACP |
Turner Syndrome |
|
|
Design of the New InsiGHTS Trial: A Multicenter, Phase 2,
Randomized, Open-Label, Active Controlled Study to Investigate the
Safety, Tolerability, and Efficacy of Lonapegsomatropin in
Prepubertal Individuals with Turner SyndromePoster,
Thursday, June 15, 12:30 - 1:30 pm (CDT) Session P10 Poster:
THU-164 |
|
Sohair Abdelrahman, Pharm.D |
|
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative TransCon technology platform to build a
leading, fully integrated, global biopharma company focused on
making a meaningful difference in patients’ lives. Guided by its
core values of patients, science and passion, the company uses its
TransCon technologies to create new and potentially best-in-class
therapies. Ascendis is headquartered in Copenhagen, Denmark, and
has additional facilities in Germany (Heidelberg, Berlin and
Munich) and the United States (Palo Alto and Redwood City,
California, and Princeton, New Jersey). Visit ascendispharma.com to
learn more.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its TransCon technology platform to build a
leading, fully integrated, global biopharma company, and (ii)
Ascendis’ use of its TransCon technologies to create new and
potentially best-in-class therapies. Ascendis may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Ascendis makes, including
the following: dependence on third party manufacturers,
distributors and service providers for Ascendis’ products and
product candidates; unforeseen safety or efficacy results in its
development programs or on-market products; unforeseen expenses
related to commercialization of any approved Ascendis products;
unforeseen expenses related to Ascendis’ development programs;
unforeseen selling, general and administrative expenses, other
research and development expenses and Ascendis’ business generally;
delays in the development of its programs related to manufacturing,
regulatory requirements, speed of patient recruitment or other
unforeseen delays; Ascendis’ ability to obtain additional funding,
if needed, to support its business activities; the impact of
international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on its
business from the worldwide COVID-19 pandemic and ongoing conflicts
such as that in the region surrounding Ukraine and Russia. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Ascendis’
business in general, see Ascendis’ Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission (SEC) on February
16, 2023 and Ascendis’ other future reports filed with, or
submitted to, the SEC. Forward-looking statements do not reflect
the potential impact of any future licensing, collaborations,
acquisitions, mergers, dispositions, joint ventures, or investments
that Ascendis may enter into or make. Ascendis does not assume any
obligation to update any forward-looking statements, except as
required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo, and TransCon are trademarks owned by the Ascendis Pharma
group. © June 2023 Ascendis Pharma A/S.
Investor Contacts: |
|
|
Media Contact: |
Tim Lee |
|
|
Melinda Baker |
Ascendis Pharma |
|
|
Ascendis Pharma |
+1 (650) 374-6343 |
|
|
+1 (650) 709-8875 |
tle@ascendispharma.com |
|
|
media@ascendispharma.com |
ir@ascendispharma.com |
|
|
|
|
|
|
|
Patti Bank |
|
|
|
ICR Westwicke |
|
|
|
+1 (415) 513-1284 |
|
|
|
patti.bank@westwicke.com |
|
|
|
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024